Maeda K, and Mitsuya H. Development of antiviral therapeurtics for HIV-1 infection and AIDS. In: AIDS in the 21st Century” (Ed.; Hall, J.C., Hall, B.J., and Cockerell, C.J.), People’s Medical Publishing House – USA, Ltd., Shelton, CT. in press

Nishizawa R, Nishiyama T, Hisaichi K, Minamoto C, Matsunaga N, Takaoka Y, Nakai H, Jenkinson S, Kazmierski WM, Tada H, Sagawa K, Shibayama S, Fukushima D, Maeda K, and Mitsuya H. Spirodiketopiperazine-based CCR5 antagonist: Discovery of an antiretroviral drug candidate. Bioorg Med Chem Lett. [Epub ahead of print] Dec 28, 2010

Ghosh AK, Xu CX, Rao KV, Baldridge A, Agniswamy J, Wang YF, Weber IT, Aoki M, Gomez SPM, Amano M, and Mitsuya H. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors. Chem Med Chem. 5(11):1850-1854, 2010

Koh Y, Amano M, Towata T, Danish M, Leshchenko-Yashchuk S, Das D, Nakayama M, Tojo Y, Ghosh AK, and Mitsuya H. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J Virol. 84(22):11961-11969, 2010.

Nakata H, Kruhlak M, Kamata W, Ogata-Aoki H, Li J, Maeda K, Ghosh AK, and Mitsuya H. Effects of CC chemokine receptor 5 (CCR5) Inhibitors on the Dynamics of CCR5 and CC-chemokine-CCR5 interactions. Antivir Ther. 15(3):321-331, 2010

Ghosh AK, Gemma S, Simoni E, Baldridge A, Walters DE, Ide K, Tojo Y, Koh Y, Amano M, and Mitsuya H. Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands. Bioorg Med Chem Lett. 20(3):1241-1246, 2010.

Nishizawa R, Nishiyama T, Hisaichi K, Hirai K, Habashita H, Takaoka Y, Tada H, Sagawa K, Shibayama S, Maeda K, Mitsuya H, Nakai H, Fukushima D, and Toda M. Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles. Bioorg Med Chem Lett.20(2):763-766, 2010.

Dikeakos JD, Atkins KM, Thomas L, Emert-Sedlak L, Byeon IJ, Jung J, Ahn J, Wortmann MD, Kukull B, Saito M, Koizumi H, Williamson DM, Hiyoshi M, Barklis E, Takiguchi M, Suzu S, Gronenborn AM, Smithgall TE, and Thomas G. Small molecule inhibition of HIV-1-induced MHC-I downregulation identifies a temporally regulated switch in Nef action. Mol Biol Cell. 21(19):3279-3292, 2010.

Tanuma J, Hachiya A, Ishigaki K, Gatanaga H, Lien TTM, Hien ND, Kin NV, Kaku M, and Oka S. Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors. Microbes Infect. 12(14-15):1170-1177, 2010.

Mwimanzi P, Hasan Z, Tokunaga M, Gatanaga H, Oka S, and Ueno T. Naturally arising HIV-1 Nef variants conferring escape from cytotoxic T lymphocytes influence viral entry co-receptor expression and susceptibility to superinfection. Biochem Biophys Res Commun. 403(3-4):422-427, 2010.

Tojo Y, Koh Y, Amano M, Aoki M, Das D, Ghosh AK, and Mitsuya H. Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-Tetrahydrofuranylurethane that are potent against multi-pi-resistant HIV-1 variants in vitro. Antimicrob Agents Chemother.54(8): 3460–3470, 2010.

Ghosh AK, Chapsal BD, and Mitsuya H. Darunavir, a new PI with dual mechanism: from a novel drug design concept to new hope against drug-resistant HIV. In “Aspartic Acid Proteases as Therapeutic Targets: Ed. Ghosh, A.K.”, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. p 205-243, 2010.

Mitsuya H, and Ghosh AK. Development of HIV-1 protease inhibitors, antiretroviral resistance and current challenges of HIV/AIDS management. In “Aspartic Acid Proteases as Therapeutic Targets: Ed. Ghosh, A.K.”, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. p 245-262, 2010.

Kawashima Y*, Kuse N*, Gatanaga H*, Naruto T, Fujiwara M, Dohki S, Akahoshi T, Maenaka K, Goulder P, Oka S, and Takiguchi M (*equal contribution). Long-term control of HIV-1 in hemophiliacs carrying slow-progressing allele HLA-B*5101. J Virol. 84(14):7151-7160, 2010.

Koizumi H*, Hashimoto M*, Fujiwara M, Murakoshi H, Chikata T, Borghan MA, Hachiya A, Kawashima Y, Takata H, Ueno T, Oka S, and Takiguchi M (*equal contribution). Different in vivo effects of HIV-1 immunodominant epitope-specific cytotoxic T lymphocytes on selection of escape mutant viruses. J Virol. 84(11):5508-5519, 2010.

Hashimoto M, Kitano M, Honda K, Koizumi H, Dohki S, Oka S, and Takiguchi M.  Selection of escape mutation by Pol154-162-specific cytotoxic T cells among chronically HIV-1-infected HLA-B*5401-positive individuals. Hum Immunol. 71(2):123-127, 2010.

Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Takiguchi M, and Oka S. Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance. AIDS. 24(5):Fast Track15-22, 2010.

Tsukada K, Teruya K, Tasato D, Gatanaga H, Kikuchi Y, and Oka S. Raltegravir-associated perihepatitis and peritonitis: a single case report. AIDS. (correspondence) 24(1):160-161, 2010.

Yoshimura K, Harada S, Shibata J, Hatada M, Yamada Y, Ochiai C, Tamamura H, Matsushita S. Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol. 84(15):7558-7568, 2010.

Hatada M, Yoshimura K, Harada S, Kawanami Y, Shibata J, Matsushita S. Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. J Gen Virol. 91(Pt5):1335-1345, 2010.

Nagai H, Odawara T, Ajisawa A, Hagiwara S, Watanebe T, Uehira T, Uchiumi H, Yotsumoto M, Miyakawa T, Watanabe A, Kanbe T, Konishi M, Saito S, Takahama S, Tateyama M, and Okada S. Whole Brain radiation alone produces favorable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol. 84(6):499-505, 2010.